Nectar Lifesciences Limited has informed the Exchange regarding 'Revised Proceedings Of 2025-26/01St Extraordinary General Meeting ("EGM").'.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has filed revised proceedings of its EGM held on August 4, 2025, after the stock exchange pointed out that the original filing did not include the meeting's conclusion time. The EGM ran from 10:00 AM to 10:20 AM and was chaired by Dr. Surulichamy Senthilkumar, Director (R&D). Three resolutions were transacted: an ordinary resolution to appoint Dr. Senthilkumar as a Director liable to retire by rotation, a special resolution to appoint him as Wholetime Director (R&D) for three years, and a special resolution to transfer the company's business to Ceph Lifesciences Private Limited on a slump sale basis as a going concern. E-voting was open from August 1 to August 3, 2025, with a ballot poll also held at the venue. The scrutinizer, Mr. Prince Chadha, will submit results, which the company will file separately under SEBI LODR Regulation 44(3).
The key shareholder concern is the slump sale of the business to Ceph Lifesciences Private Limited — a material restructuring that could reshape the company's future operations and asset base, warranting close attention when the voting results are announced. The brief 20-minute meeting and revised filing are procedural in nature and unlikely to move the stock on their own.